Medpage Today on MSN2d
Expanded Treatment Options for Primary Biliary Cholangitis Leave Open Questions
The approval of ursodeoxycholic acid (UDCA) for primary biliary cholangitis (PBC) in 1997 marked a pivotal turning point in ...
GlobalData on MSN17d
Intercept loses Ocaliva FDA full approval bid in rare liver disease
Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...
GlobalData on MSN3d
Advanz Pharma’s liver disease drug pulled from European market after court hearing
This latest update comes after Advanz secured a suspension of the European Commission’s original revocation in September 2024 ...
FiercePharma19d
FDA rejects Intercept's ask for Ocaliva full nod in rare liver disease, but accelerated approval remains
during which a panel of outside experts nearly unanimously voted against Intercept’s request for a full approval of its farnesoid X receptor agonist. During the meeting, 13 of the FDA’s ...
pharmaphorum6d
Novartis and Allergan to combine drugs in NASH
The Swiss pharma said it is to begin a phase IIb trial of one of its Farnesoid X receptor (FXR) agonists in combination with Allergan’s cenicriviroc in NASH. A group of around half a dozen ...
pharmaphorum7y
Intercept's Ocaliva approved in EU for liver disease
Ocaliva is a potent and selective agonist of the farnesoid X receptor (FXR), which is expressed at high levels in the liver and intestine and thought to be a key regulator of bile acid ...
Baylor College of Medicine2y
Clavia Ruth Wooton-Kee Lab
Our lab identified that excessive copper concentrations decreased metabolic nuclear receptor activity (FXR - farnesoid X receptor, HNF4a – hepatocyte nuclear factor, and LRH-1 – liver receptor homolog ...